US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug

US-based Baxter International Inc has recently announced that it had initiated a PIII clinical trial for investigational recombinant von Willebrand factor BAX 111 (rVWF). BAX 111 is a recombinant von Willebrand factor drug developed using a manufacturing method that is...read more